Compare PLUS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLUS | MLYS |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 1996 | 2023 |
| Metric | PLUS | MLYS |
|---|---|---|
| Price | $83.88 | $27.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $47.33 |
| AVG Volume (30 Days) | 178.9K | ★ 1.1M |
| Earning Date | 02-04-2026 | 02-12-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | ★ 28.72 | N/A |
| EPS | ★ 5.03 | N/A |
| Revenue | ★ $2,407,459,000.00 | N/A |
| Revenue This Year | $14.37 | N/A |
| Revenue Next Year | $3.17 | N/A |
| P/E Ratio | $14.95 | ★ N/A |
| Revenue Growth | ★ 15.93 | N/A |
| 52 Week Low | $53.83 | $8.24 |
| 52 Week High | $93.98 | $47.65 |
| Indicator | PLUS | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 34.24 |
| Support Level | $82.90 | $28.17 |
| Resistance Level | $90.78 | $32.21 |
| Average True Range (ATR) | 4.04 | 1.61 |
| MACD | -0.25 | -0.16 |
| Stochastic Oscillator | 31.62 | 4.29 |
ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.